Ultragenyx Pharmaceutical Inc. RARE announced that the FDA has approved UX007 (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). The drug will be marketed under the brand name,Dojolvi. The approval date comes a month ahead of the action date of Jul 31.
Ultragenyx expects Dojolvi to be available to patients in the next 30 days.
Long-chain fatty acid oxidation disorders are a group of rare conditions that prevent the body from breaking down certain fats into energy, leaving patientswith low blood sugar, muscle ruptures, muscle weakness and heart disease.
The approval of the drug will lead to increased sales for the company.
Shares of Ultragenyx have surged 83.1% year to date compared with the industry’s growth of 12.5%.
This is the second approval in June 2020 that the company received fromthe FDA for a rare disease, which had no approved therapy. In June, the FDA also approved the company’s Crysvita to treat tumor-induced osteomalacia, which is a rare disease that causes weakened or soft bones.
The company also has some gene therapy candidates in its pipeline. These include DTX301, which is an adeno-associated virus 8 (AAV8) being evaluated for the treatment of patients with Ornithine transcarbamylase (OTC) deficiency. DTX401 is also an AAV8 gene-therapy candidate, currently being evaluated for the treatment of patients with glycogen storage disease type Ia (GSDIa).
Further, the company has an agreement with Bayer BAYRY to develop adeno-associated virus gene therapies, one of which isDTX 201, for the treatment of hemophilia A.
Ultragenyx Pharmaceutical Inc. Price
Ultragenyx Pharmaceutical Inc. price | Ultragenyx Pharmaceutical Inc. Quote
Zacks Rank and Stocks to Consider
Ultragenyx is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Emergent Biosolutions Inc. EBS and Ligand Pharmaceuticals Inc. LGND, both carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $3.43 to $4.03 for 2020 and from $3.54 to $3.73 for 2021 in the past 60 days.
Ligand Pharmaceuticals’ earnings per share estimates have increased from $3.45 to $3.70 for 2020 and from $4.00 to $4.40 for 2021 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research